Iovance Biotherapeutics, Inc.
IOVA
$2.83
$0.155.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -116.16M | -78.56M | -83.54M | -97.10M | -112.98M |
| Total Depreciation and Amortization | 11.07M | 11.69M | 11.15M | 10.86M | 9.91M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.03M | 31.56M | 26.74M | 26.52M | 13.34M |
| Change in Net Operating Assets | -17.63M | -37.98M | -13.32M | -38.71M | -32.55M |
| Cash from Operations | -103.69M | -73.30M | -58.97M | -98.43M | -122.28M |
| Capital Expenditure | -6.21M | -4.17M | -2.29M | -442.00K | -4.17M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | 0.00 | 0.00 | -52.57M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 22.08M | 27.85M | -46.51M | 40.66M | -54.76M |
| Cash from Investing | 15.87M | 23.68M | -48.80M | 40.22M | -111.51M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 148.96M | 3.19M | 48.23M | 153.83M | 198.28M |
| Repurchase of Common Stock | -5.64M | -880.00K | -6.28M | -1.00M | -4.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 143.32M | 2.31M | 41.95M | 152.83M | 193.58M |
| Foreign Exchange rate Adjustments | 508.00K | -1.18M | 1.25M | -125.00K | -491.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.00M | -48.49M | -64.57M | 94.49M | -40.70M |